Cargando…

Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era

Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to...

Descripción completa

Detalles Bibliográficos
Autores principales: PABO, WILLY LE ROI TOGNA, NJUME, DEBIMEH, NDIP, ROLAND NDIP, TAKOU, DÉSIRÉ, SANTORO, MARIA-MERCEDES, CHENWI, COLLINS, BELOUMOU, GRACE, SEMENGUE, EZECHIEL NGOUFACK JAGNI, NKA, ALEX DURAND, KA'E, AUDE CHRISTELLE, TETO, GEORGES, DAMBAYA, BEATRICE, DJUPSA, SANDRINE, NYASA, RAYMOND BABILA, ANGUECHIA, DAVY HYACINTHE GOUISSI, KAMTA, CEDRIC, BALA, LIONEL, LAMBO, VIRGINIE, SOSSO, SAMUEL MARTIN, COLIZZI, VITTORIO, PERNO, CARLO FEDERICO, FOKAM, JOSEPH, NDJOLO, ALEXIS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658463/
https://www.ncbi.nlm.nih.gov/pubmed/38020274
http://dx.doi.org/10.4081/jphia.2023.2612
_version_ 1785137422707720192
author PABO, WILLY LE ROI TOGNA
NJUME, DEBIMEH
NDIP, ROLAND NDIP
TAKOU, DÉSIRÉ
SANTORO, MARIA-MERCEDES
CHENWI, COLLINS
BELOUMOU, GRACE
SEMENGUE, EZECHIEL NGOUFACK JAGNI
NKA, ALEX DURAND
KA'E, AUDE CHRISTELLE
TETO, GEORGES
DAMBAYA, BEATRICE
DJUPSA, SANDRINE
NYASA, RAYMOND BABILA
ANGUECHIA, DAVY HYACINTHE GOUISSI
KAMTA, CEDRIC
BALA, LIONEL
LAMBO, VIRGINIE
SOSSO, SAMUEL MARTIN
COLIZZI, VITTORIO
PERNO, CARLO FEDERICO
FOKAM, JOSEPH
NDJOLO, ALEXIS
author_facet PABO, WILLY LE ROI TOGNA
NJUME, DEBIMEH
NDIP, ROLAND NDIP
TAKOU, DÉSIRÉ
SANTORO, MARIA-MERCEDES
CHENWI, COLLINS
BELOUMOU, GRACE
SEMENGUE, EZECHIEL NGOUFACK JAGNI
NKA, ALEX DURAND
KA'E, AUDE CHRISTELLE
TETO, GEORGES
DAMBAYA, BEATRICE
DJUPSA, SANDRINE
NYASA, RAYMOND BABILA
ANGUECHIA, DAVY HYACINTHE GOUISSI
KAMTA, CEDRIC
BALA, LIONEL
LAMBO, VIRGINIE
SOSSO, SAMUEL MARTIN
COLIZZI, VITTORIO
PERNO, CARLO FEDERICO
FOKAM, JOSEPH
NDJOLO, ALEXIS
author_sort PABO, WILLY LE ROI TOGNA
collection PubMed
description Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm(3)), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations.
format Online
Article
Text
id pubmed-10658463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-106584632023-10-01 Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era PABO, WILLY LE ROI TOGNA NJUME, DEBIMEH NDIP, ROLAND NDIP TAKOU, DÉSIRÉ SANTORO, MARIA-MERCEDES CHENWI, COLLINS BELOUMOU, GRACE SEMENGUE, EZECHIEL NGOUFACK JAGNI NKA, ALEX DURAND KA'E, AUDE CHRISTELLE TETO, GEORGES DAMBAYA, BEATRICE DJUPSA, SANDRINE NYASA, RAYMOND BABILA ANGUECHIA, DAVY HYACINTHE GOUISSI KAMTA, CEDRIC BALA, LIONEL LAMBO, VIRGINIE SOSSO, SAMUEL MARTIN COLIZZI, VITTORIO PERNO, CARLO FEDERICO FOKAM, JOSEPH NDJOLO, ALEXIS J Public Health Afr Original Article Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm(3)), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations. PAGEPress Publications, Pavia, Italy 2023-10-01 /pmc/articles/PMC10658463/ /pubmed/38020274 http://dx.doi.org/10.4081/jphia.2023.2612 Text en Copyright © 2023, the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
spellingShingle Original Article
PABO, WILLY LE ROI TOGNA
NJUME, DEBIMEH
NDIP, ROLAND NDIP
TAKOU, DÉSIRÉ
SANTORO, MARIA-MERCEDES
CHENWI, COLLINS
BELOUMOU, GRACE
SEMENGUE, EZECHIEL NGOUFACK JAGNI
NKA, ALEX DURAND
KA'E, AUDE CHRISTELLE
TETO, GEORGES
DAMBAYA, BEATRICE
DJUPSA, SANDRINE
NYASA, RAYMOND BABILA
ANGUECHIA, DAVY HYACINTHE GOUISSI
KAMTA, CEDRIC
BALA, LIONEL
LAMBO, VIRGINIE
SOSSO, SAMUEL MARTIN
COLIZZI, VITTORIO
PERNO, CARLO FEDERICO
FOKAM, JOSEPH
NDJOLO, ALEXIS
Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
title Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
title_full Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
title_fullStr Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
title_full_unstemmed Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
title_short Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
title_sort genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in cameroon: implications in the dolutegravir-era
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658463/
https://www.ncbi.nlm.nih.gov/pubmed/38020274
http://dx.doi.org/10.4081/jphia.2023.2612
work_keys_str_mv AT pabowillyleroitogna genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT njumedebimeh genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT ndiprolandndip genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT takoudesire genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT santoromariamercedes genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT chenwicollins genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT beloumougrace genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT semengueezechielngoufackjagni genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT nkaalexdurand genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT kaeaudechristelle genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT tetogeorges genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT dambayabeatrice genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT djupsasandrine genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT nyasaraymondbabila genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT anguechiadavyhyacinthegouissi genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT kamtacedric genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT balalionel genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT lambovirginie genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT sossosamuelmartin genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT colizzivittorio genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT pernocarlofederico genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT fokamjoseph genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera
AT ndjoloalexis genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera